Press Releases - 2025-12-02

Date	Title	Company
02-Dec-2025	Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045	ACCESS Newswire
02-Dec-2025	Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate	Andrew Lloyd Associates
02-Dec-2025	AIML Subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield(TM) and Insight360(TM) for Elite Athlete Cardiac Performance Testing	ACCESS Newswire
02-Dec-2025	Avel eCare Welcomes Pat Gundersen as New Chief Revenue Officer	ACCESS Newswire
02-Dec-2025	CBD Life Sciences Inc. (CBDL) CEO Lisa Nelson Interviews With The Morning Show	ACCESS Newswire
02-Dec-2025	GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases	Newswire
02-Dec-2025	Dental Regeneration Market Trends: In-Depth Analysis of Market Growth & Forecast Up To 2029	Medi-Tech Insights
02-Dec-2025	Live Cell Imaging Market Analysis & Forecast To 2029 By Key Players, Share, Trend, Segmentation, Top Leaders and Regional	Medi-Tech Insights
02-Dec-2025	Lung Cancer Diagnostics Market is Attribute to Reach CAGR of approximately 7% Revenues by 2030	Medi-Tech Insights
02-Dec-2025	Cloud Computing in Healthcare Market to Witness a Leap by Leaching CAGR of approximately 16% By The End Of 2030	Medi-Tech Insights
02-Dec-2025	Bayer Welcomes Solicitor General Support for U.S. Supreme Court Review	Businesswire
02-Dec-2025	With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive	Businesswire
02-Dec-2025	Faron Pharmaceuticals Ltd: Grant of Options	ACCESS Newswire
02-Dec-2025	GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases	ACCESS Newswire